Comparison of time to novel therapy and ASCT initiation, using Kaplan-Meier analyses. (A) Time to novel therapy, where novel therapies included lenalidomide, pomalidomide, bortezomib, and carfilzomib. (B) Time to ASCT. Patients (pts) were censored if they reached the end of Medicare parts A, B, or D eligibility or data availability or death without event occurrence.